CBK:XETRCommerzbank AG Analysis
Data as of 2026-03-10 - not real-time
$25.23
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Commercial Bancgroup, Inc. (CBK) trades at $25.23, comfortably above its 200‑day SMA ($25.06) but below the 20‑day SMA ($26.18), indicating a short‑term pull‑back within a longer‑term bullish trend. The RSI of 39.9 suggests the stock is approaching oversold territory, while the MACD histogram remains negative, signaling lingering bearish momentum. Valuation metrics are compelling: a trailing P/E of 8.6 versus the industry average of 17.4, a price‑to‑book of 1.21, and a target price of $33 imply roughly 30% upside potential. Profitability is strong with a 55% operating margin, 41% net margin, and a 14.6% ROE, supported by modest revenue growth of 2.5% and a solid cash position that nearly offsets its debt. The dividend yield is modest at 0.4% and the payout ratio is effectively zero, raising questions about dividend sustainability. Volatility is elevated at 24.7% over the past 30 days, yet the stock’s beta of 0.47 points to lower systematic risk. Recent news offers no material catalysts, consisting only of routine price listings, so the outlook relies primarily on fundamentals and technical positioning.
Given the undervalued valuation, robust earnings profile, and low beta, CBK appears positioned for a rebound toward its $33 target. However, the current technical weakness and limited liquidity (average volume ~41k versus today’s 16k) suggest a cautious approach in the near term, with a preference for holding or modest buying as the price tests support around $24.56.
Given the undervalued valuation, robust earnings profile, and low beta, CBK appears positioned for a rebound toward its $33 target. However, the current technical weakness and limited liquidity (average volume ~41k versus today’s 16k) suggest a cautious approach in the near term, with a preference for holding or modest buying as the price tests support around $24.56.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price testing support near $24.56
- Negative MACD but RSI approaching oversold
- Low beta reducing market‑wide volatility exposure
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued P/E and P/B relative to peers
- Strong operating and net margins
- Target price implying ~30% upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustainable earnings with 14.6% ROE
- Low systematic risk (beta 0.47)
- Stable regional market presence with modest growth
Key Metrics & Analysis
Financial Health
Revenue Growth2.50%
Profit Margin40.95%
P/E Ratio8.6
ROE14.62%
ROA1.61%
P/B Ratio1.2
Industry P/E17.4
Technical Analysis
TrendBullish
RSI40.0
Support$24.56
Resistance$27.20
MA 20$26.18
MA 50$25.65
MA 200$25.06
MACDBearish
VolumeStable
Fear & Greed Index80.8
Valuation
Target Price$33.00
Upside/Downside30.80%
GradeUndervalued
TypeValue
Dividend Yield0.40%
Risk Assessment
Beta0.47
Volatility24.73%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.